I acknowledge your point re Pharmaxis. Their EU experience was exceptionally disappointing having only successfully negotiated pricing in a handful of countries - Germany and UK among them. They seemed to have learnt from their mistake and have now done a distribution deal. The usage of Bronchial was also too sporadic. Clinuvel have elected to go it alone, having reportedly rejected an offer from Pfizer for EU distribution. IMO Scenesse differs from Bronchitol in that there is no alternate treatment for EPP, it is an ultra orphan indication and long term usage data is available and extremely supportive.
I acknowledge slow takeup by payors is a risk to my earlier assumptions. The first 18 months since approval has been fairly slow.
Time will tell.
Ann: SCENESSE Treatment in Europe-CUV.AX, page-8
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.28 |
Change
-0.250(1.85%) |
Mkt cap ! $664.8M | |||
| Open | High | Low | Value | Volume |
| $13.55 | $13.62 | $13.25 | $1.157M | 86.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 227 | $13.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.42 | 228 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| CUV (ASX) Chart |